FDBusiness.com

Enzymotec Presents Clinical Trials Strategy For its Infant Nutrition Lipid Based Ingredients

 Breaking News
  • KK Foods Plans £5.5 Million Expansion KK Fine Foods, a leading frozen food manufacturer based at Deeside in Wales, is set to expand and diversify with support from the Welsh Government, creating an additional 40 new...
  • Nestlé Launches Fund to Boost Packaging Innovation Nestlé has announced that it will invest up to SFr2 billion (€1.86 billion) to lead the shift from virgin plastics to food-grade recycled plastics and to accelerate the development of...
  • Bosch Packaging Technology is Now Syntegon Syntegon Technology is the new name for Bosch Packaging Technology, following the sale of the former Bosch division. Headquartered in Waiblingen, Germany, Syntegon Technology’s business focus is on intelligent and...
  • Nestlé Launches New KitKat Gold in the UK Nestlé has unveiled a unique addition to its biggest confectionery brand – the new KitKat Gold. KitKat Gold is a combination of trademark crispy wafer on a smooth milk chocolate...
  • 789 Food and Drink Acquisitions in 2019 2019 broke records again for the number of food and drink transactions around the world, with 789 registered on the Zenith Global mergers and acquisitions database, an average of 15...

Enzymotec Presents Clinical Trials Strategy For its Infant Nutrition Lipid Based Ingredients

Enzymotec Presents Clinical Trials Strategy For its Infant Nutrition Lipid Based Ingredients
September 11
09:01 2012

Biotech company Enzymotec has reported that clinical trials for its lipid-based ingredient line for infant nutrition yielded positive results. This plan is part of a comprehensive business development strategy to develop and market directly or through its affiliated companies a line of products mimicking the vital lipids found in mother’s milk, such as triglyceride, phospholipids and long-chain polyunsaturated fatty acids (LCPUFA).Enzymotec intends to publish four new scientific articles on its lipid-based ingredients for infant nutrition in peer-reviewed journals in the coming months. These large-scale clinical research trials were conducted on newborn term infants in several institutes worldwide. Clinical results already have been presented at leading professional conferences.

One of the studies recently completed was a controlled clinical trial on InFat®. InFat is a beta-palmitate ingredient that successfully mimics the fat composition and properties of human milk fat. It enables easy digestion and optimized uptake of calcium, fat recovery and energy. InFat is marketed by Advanced Lipids, a joint venture between AAK and Enzymotec. The study was the first testing the positive effect of a commercial term-infant formula containing beta-palmitate on Chinese infants’ well-being. It was conducted by Professor Chen Yu-Ming, the principle investigator at SunYat-Sen Universityand in collaboration with Enzymotec.

“The clinical trials plan represents Enzymotec’s ongoing commitment to explore the special characteristics of human milk and demonstrate its lipid-based ingredients’ health benefits on various infant populations,” says Yael Lifshitz, PhD, Director of R&D, of Enzymotec Infant Nutrition. “We developed this innovative ingredient and educated the premium infant formula market over the last several years. Enzymotec invested 10% of its revenue in research and development—a percentage considered among the highest in the industry.”


Warning: count(): Parameter must be an array or an object that implements Countable in /home/fdbusiness/public_html/wp-content/themes/legatus-theme/includes/single/post-tags.php on line 5
Share

About Author

mike

mike

Related Articles

Food & Drink Business Conference & Exhibition 2016

Upcoming Events

[eventlist]

find food jobs

The Magazine

F&D Business Preferred Suppliers

New Subscriber

Subscribe Here



Advertisements